Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma ; volume:9 ; number:1 ; day:12 ; month:1 ; year:2024 ; pages:1-14 ; date:12.2024
Signal transduction and targeted therapy ; 9, Heft 1 (12.1.2024), 1-14, 12.2024
- Urheber
-
Yu, Zhengyu
Li, Hexian
Lu, Qizhong
Zhang, Zongliang
Tong, Aiping
Niu, Ting
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-023-01702-2
- URN
-
urn:nbn:de:101:1-2024032210021159018241
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yu, Zhengyu
- Li, Hexian
- Lu, Qizhong
- Zhang, Zongliang
- Tong, Aiping
- Niu, Ting
- SpringerLink (Online service)
Ähnliche Objekte (12)
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
CAR-T cell therapy in Multiple Myeloma: current status and future challenges
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer
CAR-T cells in multiple myeloma: current status
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies
Carborane Analogues of Fenoprofen Exhibit Improved Antitumor Activity
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Preclinical development of CD126 CAR-T cells with broad antitumor activity
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies